米格列奈钙

更新时间：2025-08-26 21:17:13

米格列奈钙结构式	常用名	米格列奈钙	英文名	Mitiglinide (Calcium)
	CAS号	145525-41-3	分子量	334.44
	密度	1.175	沸点	519.6ºC at 760 mmHg
	分子式	C₁₉H₂₄NO₃Ca_0.5	熔点	146-148ºC
	MSDS	美版	闪点	268ºC

米格列奈钙用途

Mitiglinide(KAD-1229; S21403)是KATP通道拮抗剂,具有抗2型糖尿病活性。

中文名	米格列奈钙
英文名	Calcium 2-benzyl-4-((3aR,7aS)-hexahydro-1H-isoindol-2(3H)-yl)-4-oxobutanoate
中文别名	米格列奈 \| 双(2S)-2-苄基-3-(顺式全氢异吲哚-2-羰基)丙酸单钙盐
英文别名	更多

描述	Mitiglinide(KAD-1229; S21403)是KATP通道拮抗剂,具有抗2型糖尿病活性。
相关类别	信号通路 >> 跨膜转运 >> 钾通道研究领域 >> 代谢疾病
参考文献	[1]. Kiyoshi Ichikawa, Tokuhisa Yamato, Kazuma Ojima, et al. Effect Of Kad-1229, A Novel Hypoglycaemic Agent, On Plasma Glucose Levels After Meal Load In Type 2 Diabetic Rats. Clinical and Experimental Pharmacology and Physiology. 2002, 29 (5-6): 423-427 [2]. Sunaga Y, Gonoi T, Shibasaki T, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.European Journal of Pharmacology.2001, 431(1):119 [3]. Kiyoshi Ichikawa, Kazuyasu Maruyama, Makoto Murakami, et al. Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, a novel hypoglycemic agent. European Journal of Pharmacology.2001, 3(23): 331-338 [4]. Ohnota H, Kitamura T, Kinukawa M, et al. A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Japanese Journal of Phar [5]. Hideo Mogamia, Hiroshi Shibataa, Romi Nobusawaa, et al. Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic β-cell line, MIN 6 cell.. European Journal of Pharmacology: Molecular Pharmacology. 1994, 269(3): 293-29

描述

Mitiglinide(KAD-1229; S21403)是KATP通道拮抗剂,具有抗2型糖尿病活性。

相关类别

信号通路 >> 跨膜转运 >> 钾通道

研究领域 >> 代谢疾病

参考文献

[1]. Kiyoshi Ichikawa, Tokuhisa Yamato, Kazuma Ojima, et al. Effect Of Kad-1229, A Novel Hypoglycaemic Agent, On Plasma Glucose Levels After Meal Load In Type 2 Diabetic Rats. Clinical and Experimental Pharmacology and Physiology. 2002, 29 (5-6): 423-427

[2]. Sunaga Y, Gonoi T, Shibasaki T, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.European Journal of Pharmacology.2001, 431(1):119

[3]. Kiyoshi Ichikawa, Kazuyasu Maruyama, Makoto Murakami, et al. Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, a novel hypoglycemic agent. European Journal of Pharmacology.2001, 3(23): 331-338

[4]. Ohnota H, Kitamura T, Kinukawa M, et al. A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Japanese Journal of Phar

[5]. Hideo Mogamia, Hiroshi Shibataa, Romi Nobusawaa, et al. Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic β-cell line, MIN 6 cell.. European Journal of Pharmacology: Molecular Pharmacology. 1994, 269(3): 293-29

密度	1.175
沸点	519.6ºC at 760 mmHg
熔点	146-148ºC
分子式	C₁₉H₂₄NO₃Ca_0.5
分子量	334.44
闪点	268ºC
PSA	102.45000
LogP	5.59450
InChIKey	KWKIVJHIPMALGE-VNMUXGFYSA-N
SMILES	O=C(O)C(CC(=O)N1CC2CCCCC2C1)Cc1ccccc1.[Ca]
外观性状	白色晶体粉末
蒸汽压	1.27E-11mmHg at 25°C
储存条件	room temp

危害码 (欧洲)	Xi
风险声明 (欧洲)	R36/37/38
安全声明 (欧洲)	36
危险品运输编码	NONH for all modes of transport
海关编码	2942000000

海关编码	2942000000

Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial.

Diabetes Obes. Metab. 14(2) , 187-9, (2012)

This study was performed to examine the efficacy and safety of mitiglinide in type 2 diabetes patients (T2DM). Enrolled patients had received treatment with diet and exercise in the previous 3 months ...

Comparison of the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by PK/PD analysis in rats.

Eur. J. Drug Metab. Pharmacokinet. 37(1) , 9-15, (2012)

Nateglinide and mitiglinide are immediate short-acting insulinotropic agents. Both are administered preprandially to control postprandial hyperglycemia. Glinide drugs are characterized by immediate on...

Variations in tissue selectivity amongst insulin secretagogues: a systematic review.

Diabetes Obes. Metab. 14(2) , 130-8, (2012)

Insulin secretagogues promote insulin release by binding to sulfonylurea receptors on pancreatic β-cells (SUR1). However, these drugs also bind to receptor isoforms on cardiac myocytes (SUR2A) and vas...